Tejeda DY, del Río MY, Álvarez VH, Coca PD, Núñez CAC

Language: Spanish
References: 10
Page: 4045-4050
PDF size: 42.89 Kb.

ABSTRACT

Hunter syndrome or mucopolysaccharidosis Type II is an inborn error of mucopolyssacharide metabolism, caused by deficiency of the lysosomal enzyme iduronatesulfatase, which determines serious clinical manifestations, multisystem damage and premature death. Due to its hereditary character, patients with this condition should be advised; therefore, a proposal of genetic counseling directed to couples and families at risk of having children with this condition was made, for which the basic components of this process such as diagnosis, risk estimation, communication and support or foundation were taken into account; also, the established ethical principles were respected. Likewise, a comprehensive and updated review on the disease was conducted and a fact sheet was developed with those aspects to be considered, in order to achieve a proper understanding by couples and families affected.

REFERENCES

1. Mabe P. Las Mucopolisacaridosis. Rev chil nutr. 2004;31(1):8-16.

2. Menéndez Saínz C, Zaldívar Muñoz C, González-Quevedo Monteagudo A. Errores innatos del metabolismo. Enfermedades lisosomales. Rev Cubana Pediatr. 2002;74(1):68-76.

3. Guía para el diagnóstico, seguimiento y tratamiento de la mucopolisacaridosis de tipo II (MPS-II) o Enfermedad de Hunter. Arch argent pediatr. 2011[citado Mar 2013];109(2).

4. Arias Eulate JC, Angulo Flores MD, Rueda Muñoz Z, Ghunter Paz. Síndrome de Hunter Mucopolisacaridosis (II): reporte de un caso. Rev Cient Cienc Méd. 2011;14(1):40-2.

5. Rojas Betancourt IA. Prevención de las enfermedades genéticas y asesoramiento genético. En: Lantigua Cruz A, Hernández Fernández R, Quintana Aguilar J, Morales Peralta E, Barrios García B, Rojas Betancourt IA, et al. Introducción a la Genética Médica. La Habana: Editorial de Ciencias Médicas;2006. p. 240-69.

6. Mueller RF, Young ID. Asesoramiento genético. En: Emery’s. Genética Médica. 10 ed. Madrid: Barbán Libros. 2001. p. 237-43.

7. Beers M, Berkow R. Trastornos endocrinos y metabólicos. En: Manual de Merck de diagnóstico y tratamiento. 10 ed. España: Ediciones Harcourt;1999. p.153.

8. Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng CM, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med. 2006;8(8):465-73.

9. Rojas Betancourt IA. Bioética y Genética. Rev Cubana Genet Comunit. 2007;1(1):9- 14.

10. Muenzer J, Gucsavas-Calikoglu M, Mccandless SE, Schuetz TJ, Kimura A. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Genet Metab. 2007;90(3):329-37.